** Shares of Novavax fall 2.57% to $6.87, in a second straight session
** European Medicines Agency director Emer Cooke said the agency expects to make a decision on co's updated COVID vaccine in October
** The agency began its evaluation on Aug. 24 and the vaccine was still under review
** The shot is also under review by the U.S. FDA
** NVAX shares have fallen ~12% since FDA authorized the use of vaccines from rivals Pfizer /BioNTech and Moderna
** Stock down ~33% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments